

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Koren Ofir</u> (Last) (First) (Middle) <u>C/O NANO-X IMAGING LTD., OFER TECH PARK</u> <u>94 SHLOMO SHMELTZER ROAD</u> (Street) <u>PETACH TIKVA</u> <u>4970602</u> (City) (State) (Zip) <u>ISRAEL</u> (Country)	2. Issuer Name and Ticker or Trading Symbol <u>Nano-X Imaging Ltd. [NNOX]</u> Foreign Trading Symbol [N/A]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>General Manager, ARC Division</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/10/2026</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	10/10/2026		A ⁽¹⁾		28,283	A	\$0	28,283 ⁽²⁾	D	
Ordinary Shares ⁽³⁾								10,000	D	
Ordinary Shares ⁽³⁾								10,000 ⁽⁴⁾	D	
Ordinary Shares ⁽³⁾								39,474 ⁽⁵⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy ordinary shares) ⁽³⁾	\$49.68						(6)	01/18/2031	Ordinary shares	100,000		100,000	D	
Stock Option (right to buy ordinary shares) ⁽³⁾	\$17.63						(7)	03/28/2032	Ordinary shares	25,000		25,000	D	
Stock Option (right to buy ordinary shares) ⁽³⁾	\$11.52						(8)	05/23/2033	Ordinary shares	33,500		33,500	D	

Explanation of Responses:

1. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 28,283 ordinary shares represented by 28,283 restricted share units ("RSUs"), pursuant to the Issuer's 2019 Equity Incentive Plan.
2. The 28,283 RSUs reported in this row vest and settle for underlying ordinary shares in four equal semi-annual installments of 25% each following the vesting commencement date of August 13, 2026-- on February 13, 2027, August 13, 2027, February 13, 2028 and August 13, 2028, subject, in each case, to the Reporting Person's continuous employment by the Issuer as of the applicable vesting date, such that by the two-year anniversary of the vesting commencement date (August 13, 2028) all underlying shares will be issued to the Reporting Person.
3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
4. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on April 16, 2024 and that vest and settle for underlying ordinary shares in

16 equal quarterly installments (each for 6.25% of the RSUs granted) such that by the four-year anniversary of the grant date (April 16, 2028) all underlying shares will be issued to the Reporting Person.

5. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on February 5, 2026, of which 50% vest and settle for underlying ordinary shares on the 12-month anniversary of the grant date (February 5, 2027) and the remaining 50% on the 24-month anniversary of the grant date (February 5, 2028).

6. The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report.

7. The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and are fully vested and exercisable as of the date of this report.

8. The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable by the four-year anniversary of the grant date (May 23, 2027).

Remarks:

Exhibit 24.1 - Power of Attorney

/s/ Marina Gofman Feler,
attorney-in-fact

10/13/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Marina Gofman Feler, Chief Legal Officer of Nano-X Imaging Ltd. (the “**Company**”), with full power of substitution, signing individually, the undersigned’s true and lawful attorney-in-fact and agent to:

1. Prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the Securities and Exchange Commission (the “**SEC**”) Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended and the rules and regulations thereunder (the “**Exchange Act**”) in the undersigned’s capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;
2. Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4, or 5, (including any amendments thereto) and timely file such forms with the SEC, and any stock exchange, self-regulatory association or similar authority; and
3. Take any other action of any nature whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, and her substitutes, in serving in such capacity at the request of the undersigned, is not assuming (nor is the Company assuming) any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) as to the attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of March, 2026.

By: /s/ Ofir Koren

Name: Ofir Koren